Phaseline

Companies › Elevar Therapeutics

Elevar Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Lirafugratinib
FGFR2 inhibitor
FGFR2Phase 2FGFR2 Gene Fusion/RearrangementSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07359820LirafugratinibPhase 2FGFR2 Gene Fusion/RearrangementOncologySep 2027

From the company's SEC filings

Complete response letters from FDA

Targets

FGFR2 (1)

Companies with the same targets

Tyra Biosciences KinoTeck Therapeutics AstraZeneca Johnson & Johnson (Janssen) Hangzhou Zhongmei Huadong Pharmaceutical Taiho Oncology BeOne Medicines Exelixis QED Therapeutics, a BridgeBio company TransThera Sciences (Nanjing)

Companies built like this

Tyra Biosciences TransThera Sciences (Nanjing) Shanghai Guangsheng Biopharmaceutical VIVUS Panbela Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.